AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On Dec. 12, Morgan Stanley raised the company’s price target for AbbVie to $269 from $261 with an Overweight rating on the stock.
Early on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, up from $225. The firm highlighted AbbVie’s strong growth momentum and consistent operational execution. The company downplayed concerns about competitive pressure from Tremfya, saying it is unlikely to pose a significant threat to Skyrizi’s market dominance.
In Q3 2025, AbbVie Inc. (NYSE:ABBV) reported total net revenue of ~$15.8 billion, up 9.10% year-over-year. This performance was driven by the explosive growth of new immunology and neuroscience treatments. The company also earned $1.86 per share, beating estimates by $0.08. The immunology segment continued to be the company’s driver, generating $7.9 billion in revenue, an increase of 11.2%.
This growth was driven by Skyrizi, which saw sales increase 46% to $4.7 billion, and Rinvoq, which increased 34.1% to ~$2.2 billion. These gains effectively cushioned the decline of Humira, which fell 55.7% to $993 million as biosimilar versions continued to erode its market share. Meanwhile, the oncology sector was stable at $1.7 billion in revenue, as growth in newer drugs like Venclexta offset the impact of price negotiations on Imbruvica.
AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company engaged in the research and development, manufacturing, marketing and sale of medicines and therapies worldwide.
While we recognize ABBV’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.